List of Excipients in API UPADACITINIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing UPADACITINIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AbbVie Inc | RINVOQ | upadacitinib | 0074-2306 | CELLULOSE, MICROCRYSTALLINE | 2036-10-17 |
| AbbVie Inc | RINVOQ | upadacitinib | 0074-2306 | FERRIC OXIDE RED | 2036-10-17 |
| AbbVie Inc | RINVOQ | upadacitinib | 0074-2306 | FERROSOFERRIC OXIDE | 2036-10-17 |
| AbbVie Inc | RINVOQ | upadacitinib | 0074-2306 | HYPROMELLOSE | 2036-10-17 |
| AbbVie Inc | RINVOQ | upadacitinib | 0074-2306 | MAGNESIUM STEARATE | 2036-10-17 |
| AbbVie Inc | RINVOQ | upadacitinib | 0074-2306 | MANNITOL | 2036-10-17 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for UPADACITINIB
Excipient focus: CELLULOSE, MICROCRYSTALLINE
UPADACITINIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
UPADACITINIB drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
UPADACITINIB drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
UPADACITINIB drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
UPADACITINIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
UPADACITINIB drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
UPADACITINIB drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
UPADACITINIB drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
UPADACITINIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
UPADACITINIB drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TARTARIC ACID
UPADACITINIB drug variants containing TARTARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing TARTARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
UPADACITINIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | upadacitinib | 0074-2306 |
| >Company | >Ingredient | >NDC |
UPADACITINIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
